SCHEMBL4833761

SCHEMBL4833761

NC1c2ccsc2N=CN1c1ccc(NC(=O)[C@H]2C[C@@H]2c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN3A Q9NY46 4/20 0.50
▸ DEGS1 O15121 1/20 0.49
▸ NAMPT P43490 5/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CYP3A4 P08684 3/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ HDAC3 O15379 2/20 0.40
▸ NCOR2 Q9Y618 2/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831088 1.00 SCN3A (0.50) SCN3ADEGS1NAMPTSMN1; SMN2ALDH1A1
SCHEMBL6706628 1.00 SCN3A (0.50) SCN3ADEGS1NAMPTSMN1; SMN2ALDH1A1
SCHEMBL4835303 0.81 RAB9A (0.43) SMN1; SMN2LMNAHTTNPC1RAB9A
SCHEMBL4831067 0.75 DDX3X (0.44) SMN1; SMN2ALDH1A1GAAHTTNPC1
SCHEMBL4825817 0.73 PKM (0.45) SMN1; SMN2MEN1KMT2A
SCHEMBL4825661 0.71 MAPT (0.48) SMN1; SMN2ALDH1A1LMNAGAAHTT
SCHEMBL4831085 0.70 SCN3A (0.51) SCN3ADEGS1NAMPTSMN1; SMN2ALDH1A1
SCHEMBL4833753 0.70 SCN3A (0.51) SCN3ADEGS1NAMPTSMN1; SMN2ALDH1A1
SCHEMBL4826357 0.70 CFTR (0.38) LMNAHDAC1
SCHEMBL15706299 0.70 DEGS1 (0.82) SCN3ADEGS1NAMPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK SCN3A 4862/4885DEGS1 4061/4885NAMPT 614/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR SCN3A 4852/4885DEGS1 3763/4885NAMPT 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback